{"result": "(\"entity\"<|>SOCIEDAD EUROPEA DE CARDIOLOGÍA<|>ORGANIZATION<|>The European Society of Cardiology is an organization that updates guidelines for cardiovascular disease prevention and treatment in clinical practice.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>A manual published by the Spanish Society of Endocrinology and Nutrition that provides guidelines on the treatment of dyslipidemias.)\n##\n(\"entity\"<|>AMOR FERNÁNDEZ AJ<|>PERSON<|>Amor Fernández AJ is one of the authors of the Manual de Endocrinología y Nutrición.)\n##\n(\"entity\"<|>VINAGRE TORRES I<|>PERSON<|>Vinagre Torres I is one of the authors of the Manual de Endocrinología y Nutrición.)\n##\n(\"entity\"<|>PEREA CASTILLA V<|>PERSON<|>Perea Castilla V is one of the authors of the Manual de Endocrinología y Nutrición.)\n##\n(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital of Spain where the Spanish Society of Endocrinology and Nutrition is based.)\n##\n(\"entity\"<|>ENFERMEDAD CARDIOVASCULAR<|>EVENT<|>Cardiovascular disease is a significant health issue that includes conditions such as heart attacks and strokes.)\n##\n(\"entity\"<|>DIABETES MELLITUS<|>EVENT<|>Diabetes mellitus is a chronic condition that affects how the body processes blood sugar and is a risk factor for cardiovascular disease.)\n##\n(\"entity\"<|>INSUFICIENCIA RENAL CRÓNICA<|>EVENT<|>Chronic kidney disease is a long-term condition where the kidneys do not work effectively, which can increase cardiovascular risk.)\n##\n(\"relationship\"<|>AMOR FERNÁNDEZ AJ<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Amor Fernández AJ is one of the authors of the Manual de Endocrinología y Nutrición<|>8)\n##\n(\"relationship\"<|>VINAGRE TORRES I<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Vinagre Torres I is one of the authors of the Manual de Endocrinología y Nutrición<|>8)\n##\n(\"relationship\"<|>PEREA CASTILLA V<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Perea Castilla V is one of the authors of the Manual de Endocrinología y Nutrición<|>8)\n##\n(\"relationship\"<|>SOCIEDAD EUROPEA DE CARDIOLOGÍA<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>The European Society of Cardiology's guidelines are referenced in the Manual de Endocrinología y Nutrición<|>6)\n##\n(\"relationship\"<|>SOCIEDAD EUROPEA DE CARDIOLOGÍA<|>ENFERMEDAD CARDIOVASCULAR<|>The European Society of Cardiology provides guidelines for the prevention and treatment of cardiovascular disease<|>7)\n##\n(\"relationship\"<|>DIABETES MELLITUS<|>ENFERMEDAD CARDIOVASCULAR<|>Diabetes mellitus is a significant risk factor for developing cardiovascular disease<|>9)\n##\n(\"relationship\"<|>INSUFICIENCIA RENAL CRÓNICA<|>ENFERMEDAD CARDIOVASCULAR<|>Chronic kidney disease is associated with an increased risk of cardiovascular disease<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ADO GLOMERULAR ESTIMADO (FGe) |  |  |\n|---------|-----------------------------------|-----------------|--------------|\n|         | >60 ml/min | 60-30 ml/min | <30 ml/min |\n| Atorvastatina | 10-80 mg | 10-80 mg | 10-80 mg |\n| Fluvastatina | 20-80 mg | 20-80 mg | 20-40 mg* |\n| Lovastatina | 10-80 mg | 10-80 mg | 10-20 mg* |\n| Pravastatina | 10-40 mg | 40-40 mg | 10-20 mg |\n| Rosuvastatina | 5-40 mg | 5-20 mg | 5-10 mg** |\n| Simvastatina | 5-40 mg | 5-40 mg | 5-20 mg |\n| Pitavastatina | 1-4 mg | 1-4 mg | 1-2 mg |\n| Ezetimiba | 10 mg | 10 mg | 10 mg |\n| Fenofibrato | 96 mg | 48 mg | Evitar |\n| Gemfibrozilo | 1.200 mg | 600 mg | 600 mg (evitar si FGe < 15) |\n| ω-3 | 2-4 g | 2-4 g | 2-4 g |\n\n\\* Experiencia limitada con dosis superiores en FG < 30 ml/min.\n\\** Contraindicada según ficha técnica de la AEMPS.\n\nReferencias:\n- Amor Fernández AJ, Vinagre Torres I, Perea Castilla V. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrinología y Nutrición; 2018. Capítulo 125. Tratamiento de las dislipemias. [citado 11 de noviembre de 2019]. Disponible en: https://manual.seen.es/article?id=5559fe85-9644-42fd-966a-6a43ac18103c\n\n## La Sociedad Europea de Cardiología (2016) considera como grupo de muy alto riesgo todas las siguientes situaciones excepto una. Señálela:\n\nA. Enfermedad cardiovascular documentada.\nB. Paciente con diabetes mellitus con microalbuminuria.\nC. Paciente con riesgo estimado de muerte de causa cardiovascular (SCORE) entre el 5% y el 10%.\nD. Paciente con filtrado glomerular estimado de 25 ml/min/1,73 m2.\n\n### COMENTARIO\n\nDesde la Sociedad Europea de Cardiología y otras sociedades europeas de prevención de la enfermedad cardiovascular, se actualizaron en 2016 las Guías Europeas de Prevención de la Enfermedad Cardiovascular en la Práctica Clínica, en las que se clasifica a los pacientes en cuatro grupos de riesgo cardiovascular y se marcan unas recomendaciones de tratamiento según el riesgo estimado:\n\n#### Riesgo muy alto\n\nEste grupo incluye: 1) enfermedad cardiovascular documentada clínica o por imagen. La clínica incluye infarto de miocardio previo, síndrome coronario agudo, revascularización coronaria u otros procedimientos de revascularización arterial, ictus o accidente isquémico transitorio, y enfermedad arterial periférica. La detectada por imagen incluye la existencia de una placa significativa evidenciada por angiografía coronaria o por ecografía carotídea (sin incluir incrementos del grosor de la íntima-media carotídea que no llegan a alcanzar la categoría de placa); 2) diabetes mellitus (tipo 1 o tipo 2) con lesión de órgano diana (como microalbuminuria), o con uno o más factores de riesgo cardiovascular mayores (tabaquismo, hipertensión grave o hipercolesterolemia grave); 3) insuficiencia renal crónica grave (filtrado glomerular estimado < 30 ml/min/1,73 m2), y 4) riesgo estimado de muerte de causa cardiovascular a los 10 años, calculado mediante la tablas de riesgo SCORE (en nuestro país, tablas SCORE de bajo riesgo) ≥ 10%.\n\nEl objetivo terapéutico en este grupo es un colesterol LDL < 70 mg/dl o bien una reducción de al menos un 50% si el colesterol LDL basal oscila entre 70 y 135 mg/dl.\n\n#### Riesgo alto\n\nEste grupo incluye: 1) sujetos con un factor de riesgo marcadamente elevado, como las dislipidemias familiares (en general, considerando un colesterol total > 310 mg/dl) o la hipertensión arterial grave (considerando cifras de presión arterial sistólica y diastólica > 180/110 mmHg); 2) diabetes mellitus sin otro factor de riesgo cardiovascular o lesión de órgano diana (excepto los pacientes jóvenes con diabetes tipo 1 sin factores de riesgo, que se podrían clasificar de riesgo bajo o moderado); 3) insuficiencia renal crónica moderada (filtrado glomerular estimado entre 30 y 59 ml/min/1,73 m2), y\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}